Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Beam Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Beam Therapeutics's price to sales ratio was 17.1× on Nov 11, 2026, against 46.1× a year earlier. Over the last 5 years it ranged from 4.6× to 103.3×, with a median of 26.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 17.1× | −33.4 |
| 2025 | Dec 31, 2025 | 50.4× | +44.6 |
| 2024 | Dec 31, 2024 | 5.9× | −20.6 |
| 2023 | Dec 29, 2023 | 26.5× | −3.5 |
| 2022 | Dec 30, 2022 | 30.0× | – |
See a number that looks wrong?